Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY26 results · Jul–Sep 2025
Torrent Pharmaceuticals reported revenue from operations of ₹3,302.00 crore (up 14.3% from Q2 FY25) and net profit of ₹591.00 crore (up 30.5% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,302.00 | 2,889.00 | +14.3% | 3,178.00 | +3.9% |
| Other income | (27.00) | (16.00) | Loss widened | (37.00) | Loss narrowed |
| Total income | 3,275.00 | 2,873.00 | +14.0% | 3,141.00 | +4.3% |
| Profit before tax | 791.00 | 661.00 | +19.7% | 738.00 | +7.2% |
| Net profit for the period | 591.00 | 453.00 | +30.5% | 548.00 | +7.8% |
| EPS, basic (₹) | 17.45 | 13.37 | +30.5% | 16.19 | +7.8% |
| Net margin (%) | 17.9 | 15.7 | 17.2 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,762.00 | 2,434.00 | +13.5% | 2,616.00 | +5.6% |
| Other income | (27.00) | (7.00) | Loss widened | (5.00) | Loss widened |
| Total income | 2,735.00 | 2,427.00 | +12.7% | 2,611.00 | +4.7% |
| Profit before tax | 806.00 | 670.00 | +20.3% | 742.00 | +8.6% |
| Net profit for the period | 597.00 | 460.00 | +29.8% | 551.00 | +8.3% |
| EPS, basic (₹) | 17.64 | 13.60 | +29.7% | 16.28 | +8.4% |
| Net margin (%) | 21.6 | 18.9 | 21.1 |
Consolidated
- Filed with BSE
- 07 Nov 2025, 19:21 IST
- Board meeting
- 07 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2025, 19:21 IST
- Board meeting
- 07 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Audited
- Source
- XBRL filing on BSE